Jump to content

EU approves Glaxo drug Hycamtin for lung cancer


dadstimeon

Recommended Posts

http://today.reuters.com/news/newsArtic ... CANCER.xml

Wed Feb 1, 2006 2:25 AM ET

LONDON (Reuters) - The European Commission has given approval for GlaxoSmithKline Plc's Hycamtin drug to be used as a treatment for small cell lung cancer, Europe's biggest drug maker said on Wednesday.

The medicine, which is given by infusion, is already used for ovarian cancer and its extension to lung cancer had been expected, following a positive opinion from an expert panel in November.

The drug will be used in patients with relapsed small cell lung cancer for whom re-treatment with a first-line drug regimen is not considered appropriate. Small cell lung cancer accounts for about one in five of all lung cancer cases diagnosed.

Hycamtin belongs to a class of drugs known as topoisomerase I inhibitors, which induce DNA damage and trigger the death of dividing cells.

It is considered a niche product for Glaxo but its approval is the latest in a string of recent good product news, including approval for an injectable form of the brittle bone drug Boniva and the launch of Arranon for T-cell acute lymphoblastic leukemia.

The British-based company also hopes to launch shortly a new combination diabetes pill called Avandaryl.

Looking ahead, investors are hoping for positive news later this year on three potential blockbusters -- the cervical cancer vaccine Cervarix, breast cancer pill Tykerb and blood platelet drug eltrombopag.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.